Protein C anticoagulant and cytoprotective pathways

International Journal of Hematology

Volumn 95, Issue 4, 2012, Pages 333-345

  Griffin, John H ^a   Mosnier, Laurent O ^a   Zlokovic, Berislav V ^b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Endothelial protein C receptor; Neuroprotection; Protein C; Protein S; Thrombomodulin

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 8A; HIGH DENSITY LIPOPROTEIN; NEUROPROTECTIVE AGENT; PROTEIN C; PROTEIN S;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOVASCULAR RISK; CELL PROTECTION; DRUG ACTIVITY; DRUG MECHANISM; FULMINATING PURPURA; GENE INACTIVATION; HUMAN; NONHUMAN; PROTEIN C DEFICIENCY; PROTEIN DEGRADATION; PROTEIN S DEFICIENCY; RISK FACTOR; VEIN THROMBOSIS;

ANIMALS; ANTICOAGULANTS; CYTOPROTECTION; ENZYME ACTIVATION; HUMANS; MODELS, MOLECULAR; MUTATION; PROTEIN C; PROTEIN S; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; THROMBOMODULIN; VENOUS THROMBOSIS;

EID: 84862906006     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1059-0     Document Type: Article

References (172)

1. Esmon CT. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost. 2006;32:49-60.
2. Rezaie AR. Regulation of the protein C anticoagulant and antiinflammatory pathways. Curr Med Chem. 2010;17:2059-69.
3. Riewald M, Ruf W. Science review: role of coagulation protease cascades in sepsis. Crit Care. 2003;7:123-9.
4. Weiler H, Kerschen E. Modulation of sepsis outcome with variants of activated protein C. J Thromb Haemost. 2009;7: 127-31.
5. Jackson CJ, Xue M. Activated protein C-an anticoagulant that does more than stop clots. Int J Biochem Cell Biol. 2008; 40:2692-7.
6. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood. 2007;109:3161-72.
7. van de Wouwer M, Collen D, Conway EM. Thrombomodulinprotein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol. 2004;24: 1374-83.
8. Rezende SM, Simmonds RE, Lane DA. Coagulation, inflammation, and apoptosis: different roles for protein S and the protein S-C4b binding protein complex. Blood. 2004;103: 1192-201.
9. Danese S, Vetrano S, Zhang L, Poplis VA, Castellino FJ. The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications. Blood. 2010;115:1121-30.
10. Castoldi E, Rosing J. APC resistance: biological basis and acquired influences. J Thromb Haemost. 2010;8:445-53.
11. Dahlbäck B. Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood. 2008;112:19-27.
12. Zlokovic BV, Griffin JH. Cytoprotective protein C pathways and implications for stroke and neurological disorders. Trends Neurosci. 2011;34:198-209.
13. Hackeng TM, Rosing J. Protein S as cofactor for TFPI. Arterioscler Thromb Vasc Biol. 2009;29:2015-20.
14. Jackson C, Whitmont K, Tritton S, March L, Sambrook P, Xue M. New therapeutic applications for the anticoagulant, activated protein C. Expert Opin Biol Ther. 2008;8:1109-22.
15. van Sluis GL, Buller HR, Spek CA. The role of activated protein C in cancer progression. Thromb Res. 2010;125:S138-42.
16. Gupta A, Williams MD, Macias WL, Molitoris BA, Grinnell BW. Activated protein C and acute kidney injury: selective targeting of PAR-1. Curr Drug Targets. 2009;10:1212-26.
17. Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest. 1981;68:1370-3.
18. Foster DC, Yoshitake S, Davie EW. The nucleotide sequence of the gene for human protein C. Proc Natl Acad Sci USA. 1985;82:4673-7.
19. Patracchini P, Aiello V, Palazzi P, Calzolari E, Bernardi F. Sublocalization of the human protein C gene on chromosome 2q13-q14. Hum Genet. 1989;81:191-2.
20. Griffin JH, Gruber A, Fernández JA. Reevaluation of total, free, and bound protein S and C4b-binding protein levels in plasma anticoagulated with citrate or hirudin. Blood. 1992;79:3203-11.
21. Linse S, Hardig Y, Schultz DA, Dahlbäck B. A region of vitamin K-dependent protein S that binds to C4b binding protein (C4BP) identified using bacteriophage peptide display libraries. J Biol Chem. 1997;272:14658-65.
22. Conway EM. Thrombomodulin and its role in inflammation. Semin Immunopathol. 2012;34:107-25.
23. Ito T, Maruyama I. Thrombomodulin: protectorate God of the vasculature in thrombosis and inflammation. J Thromb Haemost. 2011;9(SUPPL. 1):168-73.
24. Esmon CT, Owen WG. The discovery of thrombomodulin. J Thromb Haemost. 2004;2:209-13.
25. Jackman RW, Beeler DL, Fritze L, Soff G, Rosenberg RD. Human thrombomodulin gene is intron depleted: nucleic acid sequences of the cDNA and gene predict protein structure and suggest sites of regulatory control. Proc Natl Acad Sci USA. 1987;84:6425-9.
26. Wen DZ. Human thrombomodulin: complete cDNA sequence and chromosome localization of the gene. Biochemistry. 1987;26:4350-7.
27. Fukudome K, Esmon CT. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem. 1994;269:26486-91.
28. Simmonds RE, Lane DA. Structural and functional implications of the intron/exon organization of the human endothelial cell protein C/activated protein C receptor (EPCR) gene: comparison with the structure of CD1/major histocompatibility complex alpha1 and alpha2 domains. Blood. 1999;94:632-41.
29. Bae JS, Yang L, Manithody C, Rezaie AR. The ligand occupancy of endothelial protein C receptor switches the proteaseactivated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells. Blood. 2007;110:3909-16.
30. Russo A, Soh UJ, Paing MM, Arora P, Trejo J. Caveolae are required for protease-selective signaling by protease-activated receptor-1. Proc Natl Acad Sci USA. 2009;106:6393-7.
31. Sturn DH, Kaneider NC, Feistritzer C, Djanani A, Fukudome K, Wiedermann CJ. Expression and function of the endothelial protein C receptor in human neutrophils. Blood. 2003;102: 1499-505.
32. Yuksel M, Okajima K, Uchiba M, Horiuchi S, Okabe H. Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappa B and activator protein-1 in human monocytes. Thromb Haemost. 2002;88:267-73.
33. Pereira C, Schaer DJ, Bachli EB, Kurrer MO, Schoedon G. Wnt5A/CaMKII signaling contributes to the inflammatory response of macrophages and is a target for the antiinflammatory action of activated protein C and interleukin-10. Arterioscler Thromb Vasc Biol. 2008;28:504-10.
34. Kerschen EJ, Hernandez I, Zogg M, Jia S, Hessner MJ, Fernandez J, et al. Activated protein C targets CD8? dendritic cells to reduce the mortality of endotoxemia in mice. J Clin Invest. 2010;120:3167-78.
35. Qu D, Wang Y, Esmon NL, Esmon CT. Regulated endothelial protein C receptor shedding is mediated by tumor necrosis factor-alpha converting enzyme/ADAM17. J Thromb Haemost. 2007;5:395-402.
36. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991;64:1057-68.
37. Coughlin SR. Thrombin signaling and protease-activated receptors. Nature. 2000;407:258-64.
38. Leger AJ, Covic L, Kuliopulos A. Protease-activated receptors in cardiovascular diseases. Circulation. 2006;114:1070-7.
39. Traynelis SF, Trejo J. Protease-activated receptor signaling: new roles and regulatory mechanisms. Curr Opin Hematol. 2007; 14:230-5.
40. Coughlin SR, Camerer E. PARticipation in inflammation. J Clin Invest. 2003;111:25-7.
41. Nakanishi-Matsui M, Zheng YW, Sulciner DJ, Weiss EJ, Ludeman MJ, Coughlin SR. PAR3 is a cofactor for PAR4 activation by thrombin. Nature. 2000;404:609-13.
42. Gale AJ, Heeb MJ, Griffin JH. The autolysis loop of activated protein C interacts with factor Va and differentiates between the Arg506 and Arg306 cleavage sites. Blood. 2000;96:585-93.
43. Shen L, Villoutreix BO, Dahlbäck B. Interspecies loop grafting in the protease domain of human protein C yielding enhanced catalytic and anticoagulant activity. Thromb Haemost. 1999;82: 1078-87.
44. Friedrich U, Nicolaes GAF, Villoutreix BO, Dahlbäck B. Secondary substrate-binding exosite in the serine protease domain of activated protein C important for cleavage at Arg-506 but not at Arg-306 in factor Va. J Biol Chem. 2001;276:23105-8.
45. Rezaie AR. Exosite-dependent regulation of the protein C anticoagulant pathway. Trends Cardiovasc Med. 2003;13:8-15.
46. Gale AJ, Tsavaler A, Griffin JH. Molecular characterization of an extended binding site for coagulation factor Va in the positive exosite of activated protein C. J Biol Chem. 2002;277: 28836-40.
47. Gale AJ, Griffin JH. Characterization of a thrombomodulin binding site on protein C and its comparison to an activated protein C binding site for factor Va. Proteins. 2004;54:433-41.
48. Gale AJ, Radtke KP, Cunningham MA, Chamberlain D, Pellequer JL, Griffin JH. Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants. J Thromb Haemost. 2006;4:1315-22.
49. Gale AJ, Cramer TJ, Rozenshteyn D, Cruz JR. Detailed mechanisms of the inactivation of factor VIIIa by activated protein C in the presence of its cofactors, protein S and factor V. J Biol Chem. 2008;283:16355-62.
50. Heeb MJ, Kojima Y, Rosing J, Tans G, Griffin JH. C-terminal residues 621-635 of protein S are essential for binding to factor Va. J Biol Chem. 1999;274:36187-92.
51. Heeb MJ, Kojima Y, Hackeng TM, Griffin JH. Binding sites for blood coagulation factor Xa and protein S involving residues 493-506 in factor Va. Protein Sci. 1996;5:1883-9.
52. Harmon S, Preston RJ, Ainle FN, Johnson JA, Cunningham MS, Smith OP, et al. Dissociation of activated protein C functions by elimination of protein S cofactor enhancement. J Biol Chem. 2008;283:30531-9.
53. Mosnier LO, Zampolli A, Kerschen EJ, Schuepbach RA, Banerjee Y, Fernandez JA, et al. Hyper-antithrombotic, noncytoprotective Glu149Ala-activated protein C mutant. Blood. 2009;113:5970-8.
54. Andersson HM, Arantes MJ, Crawley JT, Luken BM, Tran S, Dahlbäck B, et al. Activated protein C cofactor function of protein S: a critical role for Asp95 in the EGF1-like domain. Blood. 2010;115:4878-85.
55. Nishioka J, Suzuki K. Inhibition of cofactor activity of protein S by a complex of protein S and C4b-binding protein. Evidence for inactive ternary complex formation between protein S, C4bbinding protein, and activated protein C. J Biol Chem. 1990; 265:9072-6.
56. Fernández JA, Heeb MJ, Griffin JH. Identification of residues 413-433 of plasma protein S as essential for binding to C4bbinding protein. J Biol Chem. 1993;268:16788-94.
57. Greengard JS, Fernández JA, Radtke KP, Griffin JH. Identification of candidate residues for interaction of protein S with C4b binding protein and activated protein C. Biochem J. 1995; 305:397-403.
58. Fernández JA, Griffin JH, Chang GT, Stam J, Reitsma PH, Bertina RM, et al. Involvement of amino acid residues 423-429 of human protein S in binding to C4b-binding protein. Blood Cells Mol Dis. 1998;24:101-12.
59. Brinkman HJ, Mertens K, van Mourik JA. Proteolytic cleavage of protein S during the hemostatic response. J Thromb Haemost. 2005;3:2712-20.
60. Chang GT, Aaldering L, Hackeng TM, Reitsma PH, Bertina RM, Bouma BN. Construction and characterization of thrombinresistant variants of recombinant human protein S. Thromb Haemost. 1994;72:693-7.
61. Heeb MJ, Mesters RM, Tans G, Rosing J, Griffin JH. Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C. J Biol Chem. 1993;268:2872-7.
62. Hackeng TM, Sere KM, Tans G, Rosing J. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci USA. 2006;103:3106-11.
63. Hackeng TM, Maurissen LF, Castoldi E, Rosing J. Regulation of TFPI function by protein S. J Thromb Haemost. 2009;7:165-8.
64. Fernandes N, Mosnier LO, Tonnu L, Heeb MJ. Zn2 ?-containing protein S inhibits extrinsic factor X activating complex independently of tissue factor pathway inhibitor (TFPI). J Thromb Haemost. 2010;8:1976-85.
65. Heeb MJ, Prashun D, Griffin JH, Bouma BN. Plasma protein S contains zinc essential for efficient activated protein C-independent anticoagulant activity and binding to factor Xa, but not for efficient binding to tissue factor pathway inhibitor. FASEB J. 2009;23:2244-53.
66. Fernández JA, Kojima K, Petäjä J, Hackeng TM, Griffin JH. Cardiolipin enhances protein C pathway anticoagulant activity. Blood Cells Mol Dis. 2000;26:115-23.
67. Bakker HM, Tans G, Janssen-Claessen T, Thomassen MC, Hemker HC, Griffin JH, et al. The effect of phospholipids, calcium ions and protein S on rate constants of human factor Va inactivation by activated human protein C. Eur J Biochem. 1992;208:171-8.
68. Griffin JH, Kojima K, Banka CL, Curtiss LK, Fernández JA. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest. 1999;103:219-27.
69. Griffin JH, Fernández JA, Deguchi H. Plasma lipoproteins, hemostasis and thrombosis. Thromb Haemost. 2001;86:386-94.
70. Deguchi H, Fernández JA, Pabinger I, Heit JA, Griffin JH. Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulant protein C pathway. Blood. 2001;97:1907-14.
71. Deguchi H, Fernández JA, Griffin JH. Neutral glycosphingolipiddependent inactivation of coagulation factor Va by activated protein C and protein S. J Biol Chem. 2002;277:8861-5.
72. Yegneswaran S, Deguchi H, Griffin JH. Glucosylceramide, a neutral glycosphingolipid anticoagulant cofactor, enhances the interaction of human-and bovine-activated protein C with negatively charged phospholipid vesicles. J Biol Chem. 2003; 278:14614-21.
73. Deguchi H, Yegneswaran S, Griffin JH. Sphingolipids as bioactive regulators of thrombin generation. J Biol Chem. 2004; 279:12036-42.
74. Oslakovic C, Norstrom E, Dahlbäck B. Reevaluation of the role of HDL in the anticoagulant activated protein C system in humans. J Clin Invest. 2010;120:1396-9.
75. Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions of HDL. Circ Res. 2006;98:1352-64.
76. Deguchi H, Pecheniuk NM, Elias DJ, Averell PM, Griffin JH. High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation. 2005; 112:893-9.
77. Eichinger S, Pecheniuk NM, Hron G, Deguchi H, Schemper M, Kyrle PA, et al. High-density lipoprotein and the risk of recurrent venous thromboembolism. Circulation. 2007;115:1609-14.
78. Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem. 1994;269:18735-8.
79. Cramer TJ, Griffin JH, Gale AJ. Factor V is an anticoagulant cofactor for activated protein C during inactivation of factor Va. Pathophysiol Haemost Thromb. 2010;37:17-23.
80. Castoldi E, Rosing J. Factor V Leiden: a disorder of factor V anticoagulant function. Curr Opin Hematol. 2004;11:176-81.
81. Nicolaes GAF, Dahlbäck B. Factor V and thrombotic disease: description of a janus-faced protein. Arterioscler Thromb Vasc Biol. 2002;22:530-8.
82. Chalmers E, Cooper P, Forman K, Grimley C, Khair K, Minford A, et al. Purpura fulminans: recognition, diagnosis and management. Arch Dis Child. 2011;96:1066-71.
83. Gladson CL, Groncy P, Griffin JH. Coumarin necrosis, neonatal purpura fulminans, and protein C deficiency. Arch Dermatol. 1987;123:1701a-6a.
84. D'Ursi P, Marino F, Caprera A, Milanesi L, Faioni EM, Rovida E. ProCMD: a database and 3D web resource for protein C mutants. BMC Bioinformatics. 2007;8:S11.
85. Saunders RE, Perkins SJ. CoagMDB: a database analysis of missense mutations within four conserved domains in five vitamin K-dependent coagulation serine proteases using a textmining tool. Hum Mutat. 2008;29:333-44.
86. Rovida E, Merati G, D'Ursi P, Zanardelli S, Marino F, Fontana G, et al. Identification and computationally-based structural interpretation of naturally occurring variants of human protein C. Hum Mutat. 2006;28:345-55.
87. Greengard JS, Fisher CL, Villoutreix B, Griffin JH. Structural basis for type I and type II deficiencies of antithrombotic plasma protein C: patterns revealed by three-dimensional molecular modelling of mutations of the protease domain. Proteins. 1994;18:367-80.
88. Comp PC, Esmon CT. Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med. 1984;311:1525-8.
89. Schwarz HP, Fischer M, Hopmeier P, Batard MA, Griffin JH. Plasma protein S deficiency in familial thrombotic disease. Blood. 1984;64:1297-300.
90. Garcia de Frutos P, Fuentes-Prior P, Hurtado B, Sala N. Molecular basis of protein S deficiency. Thromb Haemost. 2007;98:543-56.
91. Mahasandana C, Suvatte V, Marlar RA, Manco-Johnson MJ, Jacobson LJ, Hathaway WE. Neonatal purpura fulminans associated with homozygous protein S deficiency. Lancet. 1990;335: 61-2.
92. Gandrille S, Borgel D, Ireland H, Lane DA, Simmonds R, Reitsma PH, et al. Protein S deficiency: a database of mutations. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 1997;77:1201-14.
93. Hayashi T, Nishioka J, Shigekiyo T, Saito S, Suzuki K. Protein S Tokushima: abnormal molecule with a substitution of Glu for Lys-155 in the second epidermal growth factor-like domain of protein S. Blood. 1994;83:683-90.
94. Hayashi T, Nishioka J, Suzuki K. Characterization of dysfunctional protein S-Tokushima (K155 ? E) in relation to the molecular interactions required for the regulation of blood coagulation. Pol J Pharmacol. 1996;48:221-3.
95. Ikejiri M, Wada H, Sakamoto Y, Ito N, Nishioka J, Nakatani K, et al. The association of protein S Tokushima-K196E with a risk of deep vein thrombosis. Int J Hematol. 2010;92:302-5.
96. Nicolaes GA, Hackeng TM, Segers K, Rosing J. A structural model of the SHBG domain of human variant protein S Heerlen. Thromb Haemost. 2006;96:538-40.
97. Heeb MJ, Koenen RR, Fernandez JA, Hackeng TM. Direct anticoagulant activity of protein S-C4b binding protein complex in Heerlen heterozygotes and normals. J Thromb Haemost. 2004;2:1766-73.
98. Miyata T, Kimura R, Kokubo Y, Sakata T. Genetic risk factors for deep vein thrombosis among Japanese: importance of protein S K196E mutation. Int J Hematol. 2006;83:217-23.
99. Kimura R, Kokubo Y, Miyashita K, Otsubo R, Nagatsuka K, Otsuki T, et al. Polymorphisms in vitamin K-dependent gammacarboxylation-related genes influence interindividual variability in plasma protein C and protein S activities in the general population. Int J Hematol. 2006;84:387-97.
100. Hayashi T, Nishioka J, Suzuki K. Molecular mechanism of the dysfunction of protein S(Tokushima) (Lys155 ? Glu) for the regulation of the blood coagulation system. Biochim Biophys Acta. 1995;1272:159-67.
101. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA. 1993;90:1004-8.
102. Greengard JS, Sun X, Xu X, Fernández JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet. 1994;343:1361-2.
103. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutations in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-7.
104. Delvaeye M, Noris M, de Vriese A, Esmon CT, Esmon NL, Ferrell G, et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361:345-57.
105. Poort SR, Vos HL, Rosendaal FR, Bertina RM. The endothelial protein C receptor (EPCR) 23 bp insert mutation and the risk of venous thrombosis. Thromb Haemost. 2002;88:160-2.
106. Saposnik B, Lesteven E, Lokajczyk A, Esmon CT, Aiach M, Gandrille S. Alternative mRNA splicing is favored by the A3 haplotype of the EPCR gene PROCR and generates a novel soluble form of EPCR in plasma. Blood. 2008;111:3442-51.
107. Biguzzi E, Merati G, Liaw PCY, Bucciarelli P, Oganesyan N, Qu D, et al. A 23 bp insertion in the endothelial protein C receptor (EPCR) gene impairs EPCR function. Thromb Haemost. 2001;86:945-8.
108. von Depka M, Czwalinna A, Eisert R, Wermes C, Scharrer I, Ganser A, et al. Prevalence of a 23 bp insertion in exon 3 of the endothelial cell protein C receptor gene in venous thrombophilia. Thromb Haemost. 2001;86:1360-2.
109. Medina P, Navarro S, Estelles A, Espana F. Polymorphisms in the endothelial protein C receptor gene and thrombophilia. Thromb Haemost. 2007;98:564-9.
110. Medina P, Navarro S, Estelles A, Vaya A, Bertina RM, Espana F. Influence of the 4600A/G and 4678G/C polymorphisms in the endothelial protein C receptor (EPCR) gene on the risk of venous thromboembolism in carriers of factor V Leiden. Thromb Haemost. 2005;94:389-94.
111. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem. 2001;276:11199-203.
112. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science. 2002;296:1880-2.
113. Cheng T, Liu D, Griffin JH, Fernández JA, Castellino FJ, Rosen ED, et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med. 2003;9:338-42.
114. Mosnier LO, Griffin JH. Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease activated receptor-1 and endothelial cell protein C receptor. Biochem J. 2003;373:65-70.
115. Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood. 2005;105:3178-84.
116. Finigan JH, Dudek SM, Singleton PA, Chiang ET, Jacobson JR, Camp SM, et al. Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J Biol Chem. 2005;280:17286-93.
117. Kenakin T. New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat Rev Drug Discov. 2005;4: 919-27.
118. Reiter E, Ahn S, Shukla AK, Lefkowitz RJ. Molecular mechanism of b-arrestin-biased agonism at seven-transmembrane receptors. Annu Rev Pharmacol Toxicol. 2012;52:179-97.
119. Deupi X, Standfuss J. Structural insights into agonist-induced activation of G-protein-coupled receptors. Curr Opin Struct Biol. 2011;21:541-51.
120. Jalbert LR, Rosen ED, Moons L, Chan JCY, Carmeliet P, Collen D, et al. Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. J Clin Invest. 1998;102:1481-8.
121. Pendurthi UR, Rao LV. Factor VIIa interaction with endothelial cells and endothelial cell protein C receptor. Thromb Res. 2010;125:S19-22.
122. Sen P, Gopalakrishnan R, Kothari H, Keshava S, Clark CA, Esmon CT, et al. Factor VIIa bound to endothelial cell protein C receptor activates protease activated receptor-1 and mediates cell signaling and barrier protection. Blood. 2011;117:3199-208.
123. Disse J, Petersen HH, Larsen KS, Persson E, Esmon N, Esmon CT, et al. The endothelial protein C receptor supports tissue factor ternary coagulation initiation complex signaling through protease-activated receptors. J Biol Chem. 2011;286:5756-67.
124. Schuepbach RA, Riewald M. Coagulation factor Xa cleaves PAR1 and mediates signaling dependent on binding to the endothelial protein C receptor. J Thromb Haemost. 2010;8:379-88.
125. Domotor E, Benzakour O, Griffin JH, Yule D, Fukudome K, Zlokovic BV. Activated protein C alters cytosolic calcium flux in human brain endothelium via binding to endothelial protein C receptor and activation of protease activated receptor-1. Blood. 2003;101:4797-801.
126. Cheng T, Petraglia AL, Li Z, Thiyagarajan M, Zhong Z, Wu Z, et al. Activated protein C inhibits tissue plasminogen activatorinduced brain hemorrhage. Nat Med. 2006;12:1278-85.
127. Guo H, Liu D, Gelbard H, Cheng T, Insalaco R, Fernández JA, et al. Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3. Neuron. 2004;41:563-72.
128. Kerschen EJ, Fernandez JA, Cooley BC, Yang XV, Sood R, Mosnier LO, et al. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med. 2007; 204:2439-48.
129. Mosnier LO, Yang XV, Griffin JH. Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions. J Biol Chem. 2007;282:33022-33.
130. Bae JS, Yang L, Rezaie AR. Receptors of the protein C activation and activated protein C signaling pathways are colocalized in lipid rafts of endothelial cells. Proc Natl Acad Sci USA. 2007;104:2867-72.
131. Russo A, Soh UJ, Trejo J. Proteases display biased agonism at protease-activated receptors: location matters! Mol Interv. 2009;9:87-96.
132. Bae JS, Yang L, Rezaie AR. Lipid raft localization regulates the cleavage specificity of protease activated receptor 1 in endothelial cells. J Thromb Haemost. 2008;6:954-61.
133. Bae JS, Rezaie AR. Protease activated receptor 1 (PAR-1) activation by thrombin is protective in human pulmonary artery endothelial cells if endothelial protein C receptor is occupied by its natural ligand. Thromb Haemost. 2008;100:101-9.
134. Schuepbach RA, Feistritzer C, Brass LF, Riewald M. Activated protein C-cleaved protease activated receptor-1 is retained on the endothelial cell surface even in the presence of thrombin. Blood. 2008;111:2667-73.
135. Soh UJ, Trejo J. Activated protein C promotes protease-activated receptor-1 cytoprotective signaling through beta-arrestin and dishevelled-2 scaffolds. Proc Natl Acad Sci USA. 2011;108:E1372-80.
136. Baumer Y, Spindler V, Werthmann RC, Bunemann M, Waschke J. Role of Rac 1 and cAMP in endothelial barrier stabilization and thrombin-induced breakdown. J Cell Phys. 2009;220:716-26.
137. Spindler V, Schlegel N, Waschke J. Role of GTPases in control of microvascular permeability. Cardiovasc Res. 2010;87: 243-53.
138. Bir N, Lafargue M, Howard M, Goolaerts A, Roux J, Carles M, et al. Cytoprotective-selective activated protein C attenuates Pseudomonas aeruginosa-induced lung injury in mice. Am J Respir Cell Mol Biol. 2011;45:632-41.
139. Bae JS, Rezaie AR. Thrombin inhibits nuclear factor kappaB and RhoA pathways in cytokine-stimulated vascular endothelial cells when EPCR is occupied by protein C. Thromb Haemost. 2009;101:513-20.
140. Wang L, Dudek SM. Regulation of vascular permeability by sphingosine 1-phosphate. Microvasc Res. 2009;77:39-45.
141. White TC, Berny MA, Tucker EI, Urbanus RT, de Groot PG, Fernandez JA, et al. Protein C supports platelet binding and activation under flow: role of glycoprotein Ib and apolipoprotein E receptor 2. J Thromb Haemost. 2008;6:995-1002.
142. Guo H, Singh I, Wang Y, Deane R, Barrett T, Fernandez JA, et al. Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity. Eur J Neurosci. 2009;29: 1119-30.
143. Madhusudhan T, Wang H, Straub BK, Grone E, Zhou Q, Shahzad K, et al. Cytoprotective signaling by activated protein C requires protease activated receptor-3 in podocytes. Blood. 2012;119:874-83.
144. ElphickGF, Sarangi PP,HyunYM,Hollenbaugh JA,Ayala A, Biffl WL, et al. Recombinant human activated protein C inhibits integrin-mediated neutrophil migration. Blood. 2009;113:4078-85.
145. Minhas N, Xue M, Fukudome K, Jackson CJ. Activated protein C utilizes the angiopoietin/Tie2 axis to promote endothelial barrier function. FASEB J. 2010;24:873-81.
146. Zhong Z, Ilieva H, Hallagan L, Bell R, Singh I, Paquette N, et al. Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. J Clin Invest. 2009;119:3437-49.
147. Xue M, Chow SO, Dervish S, Chan YK, Julovi S, Jackson CJ. Activated protein C enhances human keratinocyte barrier integrity via sequential activation of epidermal growth factor receptor and tie2. J Biol Chem. 2011;286:6742-50.
148. Yang XV, Banerjee Y, Fernandez JA, Deguchi H, Xu X, Mosnier LO, et al. Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells. Proc Natl Acad Sci USA. 2009;106:274-9.
149. Cao C, Gao Y, Li Y, Antalis TM, Castellino FJ, Zhang L. The efficacy of activated protein C in murine endotoxemia is dependent on integrin CD11b. J Clin Invest. 2010;120:1971-80.
150. Isermann B, Vinnikov IA, Madhusudhan T, Herzog S, Kashif M, Blautzik J, et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med. 2007;13:1349-58.
151. Xu J, Zhang X, Pelayo R, Monestier M, Ammollo CT, Semeraro F, et al. Extracellular histones are major mediators of death in sepsis. Nat Med. 2009;15:1318-21.
152. Wildhagen KC, Lutgens E, Loubele ST, Ten CH, Nicolaes GA. The structure-function relationship of activated protein C. Thromb Haemost. 2011;106:1034-45.
153. Weiler H. Multiple receptor-mediated functions of activated protein C. Hamostaseologie. 2011;31:185-95.
154. Mosnier LO, Gale AJ, Yegneswaran S, Griffin JH. Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. Blood. 2004;104:1740-5.
155. Mather T, Oganessyan V, Hof P, Huber R, Foundling S, Esmon CT, et al. The 2.8 A crystal structure of Gla-domainless activated protein C. EMBO J. 1996;15:6822-31.
156. Shen L, Villoutreix BO, Dahlbäck B. Involvement of lys 62(217) and lys 63(218) of human anticoagulant protein C in heparin stimulation of inhibition by the protein C inhibitor. Thromb Haemost. 1999;82:72-9.
157. Bae JS, Yang L, Manithody C, Rezaie AR. Engineering a disulfide bond to stabilize the calcium binding loop of activated protein C eliminates its anticoagulant but not protective signaling properties. J Biol Chem. 2007;282:9251-9.
158. Yang L, Bae JS, Manithody C, Rezaie AR. Identification of a specific exosite on activated protein C for interaction with protease activated receptor 1. J Biol Chem. 2007;282: 25493-500.
159. Preston RJ, Villegas-Mendez A, Sun YH, Hermida J, Simioni P, Philippou H, et al. Selective modulation of protein C affinity for EPCR and phospholipids by Gla domain mutation. FEBS J. 2005;272:97-108.
160. Ni Ainle F, O'Donnell JS, Johnson JA, Brown L, Gleeson EM, Smith OP, et al. Activated protein C N-linked glycans modulate cytoprotective signaling function on endothelial cells. J Biol Chem. 2011;286:1323-30.
161. Guo H, Wang Y, Singh I, Liu D, Fernandez JA, Chow N, et al. Species-dependent neuroprotection by activated protein C mutants with reduced anticoagulant activity. J Neurochem. 2009;109:116-24.
162. Fernández JA, Xu X, Liu D, Zlokovic BV, Griffin JH. Recombinant murine-activated protein C is neuroprotective in a murine ischemic stroke model. Blood Cells Mol Dis. 2003;30:271-6.
163. Shibata M, Kumar SR, Amar A, Fernández JA, Hofman F, Griffin JH, et al. Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. Circulation. 2001;103:1799-805.
164. Zlokovic BV, Zhang C, Liu D, Fernández JA, Griffin JH, Chopp M. Functional recovery after embolic stroke in rodents by activated protein C. Ann Neurol. 2005;58:474-7.
165. Han MH, Hwang SI, Roy DB, Lundgren DH, Price JV, Ousman SS, et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature. 2008;451:1076-81.
166. Liu D, Cheng T, Guo H, Fernández JA, Griffin JH, Song X, et al. Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat Med. 2004;10:1379-83.
167. Villoutreix BO, Teleman O, Dahlback B. A theoretical model for the Gla-TSR-EGF-1 region of the anticoagulant cofactor protein S: from biostructural pathology to species-specific cofactor activity. J Comput Aided Mol Des. 1997;11:293-304.
168. Drakenberg T, Ghasriani H, Thulin E, Thamlitz AM, Muranyi A, Annila A, et al. Solution structure of the Ca2?-binding EGF3-4 pair from vitamin K-dependent protein S: identification of an unusual fold in EGF3. Biochemistry. 2005;44:8782-9.
169. Villoutreix BO, Dahlback B, Borgel D, Gandrille S, Muller YA. Three-dimensional model of SHBG-like region of anticoagulant protein S: new structure-function insights. Proteins. 2001;43: 203-16.
170. Arnold K, Bordoli L, Kopp J, Schwede T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics. 2006;22:195-201.
171. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol. 1993;234:779-815.
172. Pellequer JL, Gale AJ, Getzoff ED, Griffin JH. Three-dimensional model of coagulation factor Va bound to activated protein C. Thromb Haemost. 2000;84:849-57.